Clinical Trial Update: A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP） [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating exemestane tablets with ovarian function suppression in premenopausal breast cancer patients carrying CYP2D6*10 mutations is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Exemestane (Exemestane)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: CYP2D6 Polymorphism | Phase 3 | Status: UNKNOWN